Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies By dev@sirosolutions.com / December 17, 2024
Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127 By dev@sirosolutions.com / December 17, 2024
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies By dev@sirosolutions.com / December 17, 2024
